Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenue Growth Supported By A CAGR Of 26.47% Through 2030
The market for treating vasomotor menopausal symptoms (VMS) has observed a robust expansion recently, projected to increase from $19.01 billion in 2025 to $20.16 billion by 2026, reflecting a compound annual growth rate of 6.0%. This historical growth trajectory is largely attributable to several key factors: a rising incidence of menopausal symptoms, the extensive utilization of hormone replacement therapy, escalating clinical investigations into treatments targeting neurotransmitters, the broader development of women’s health services, and enhanced accessibility to specialized medical facilities.
The market encompassing treatments for vasomotor menopausal symptoms (VMS) is poised for significant expansion over the coming years, with projections indicating a valuation of $26.48 billion by 2030, reflecting a compound annual growth rate of 7.1%. This anticipated surge is fueled by several key factors including a burgeoning demand for therapeutic options that do not involve hormones, heightened public consciousness regarding menopause-specific health strategies, increased financial backing for research into women’s health issues, the wider application of remote healthcare for treatment administration, and advancements in the creation of innovative VMS therapies. During this projected timeframe, prevailing trends will likely involve a greater emphasis on the development of non-hormonal interventions, a growing inclination towards customized approaches for managing menopause, an increased utilization of digital health solutions for symptom control, the broader implementation of synergistic drug treatments, and a more pronounced consideration of the long-term safety aspects of VMS therapies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp
Vasomotor Menopausal Symptoms (VMS) Treatment Market Demand Drivers Creating New Revenue Opportunities
Anticipated advancements in the vasomotor menopausal symptom treatment sector are largely attributed to governmental strategies aimed at enhancing women’s health during menopause. These governmental programs focusing on menopausal well-being include financial support for pioneering research into the menopausal transition, strategies for disease prevention, and investigations into the pharmacological, clinical, and epidemiological dimensions of menopause. Such endeavors are integrated within wider women’s health agendas designed to tackle a range of health issues. Illustratively, in January 2023, the New South Wales Government of Australia announced a four-year investment of $40.3 million, spanning from 2022-2023 to 2025-2026, intended to establish up to sixteen new programs specifically for women experiencing significant menopausal symptoms, thereby underscoring how these governmental directives are a key catalyst for expansion within the market for treating vasomotor menopausal symptoms.
Vasomotor Menopausal Symptoms (VMS) Treatment Market Segment Analysis: What Are The Major Market Categories?
The vasomotor menopausal symptoms (vms) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) By Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) By Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) By Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) By Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines
Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends Driving Strategic Industry Expansion
In the competitive landscape of the vasomotor menopausal symptoms treatment market, leading pharmaceutical entities are actively engaged in launching innovative products, exemplified by Veozah, and securing regulatory endorsements to introduce novel therapeutic avenues and address the persistent medical requirements of individuals. The advent of new pharmaceutical interventions for menopause signifies advancements in both effectiveness and safety profiles when contrasted with established remedies. As an illustration, during May of 2023, Astellas Pharma Inc., a prominent pharmaceutical firm headquartered in Japan, obtained authorization from the Food and Drug Administration (FDA), a regulatory body within the United States, for Veozah (fezolinetant) administered at a dosage of 45 mg taken once daily, specifically targeting menopausal vasomotor symptoms (VMS) that can present with varying degrees of severity. What distinguishes this medication is its status as the inaugural nonhormonal neurokinin 3 (NK3) receptor antagonist to gain regulatory clearance for the management of VMS associated with menopause. This hormone-free therapeutic operates by inhibiting a specific neural pathway in the brain implicated in controlling these symptoms, thereby presenting a viable alternative for women experiencing these symptoms, especially those who are either unable or opt against utilizing hormone replacement therapy. The regulatory nod for Veozah underscores its promise as a groundbreaking pharmaceutical agent for the effective management of menopausal symptoms.
Vasomotor Menopausal Symptoms (VMS) Treatment Market Leading Companies Driving Competitive Growth
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc
Access The Complete Vasomotor Menopausal Symptoms (VMS) Treatment Market Report:
Vasomotor Menopausal Symptoms (VMS) Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2025. The regions covered in the vasomotor menopausal symptoms (vms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
